Display options
Cite
Guerreiro Castro S, Isenberg DA. Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. Ther Adv Musculoskelet Dis. 2017;9(3):75-85doi: 10.1177/1759720X17690474.
Guerreiro Castro, S., & Isenberg, D. A. (2017). Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. Therapeutic advances in musculoskeletal disease, 9(3), 75-85. https://doi.org/10.1177/1759720X17690474
Guerreiro Castro, Sara, and Isenberg, David A. "Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness." Therapeutic advances in musculoskeletal disease vol. 9,3 (2017): 75-85. doi: https://doi.org/10.1177/1759720X17690474
Guerreiro Castro S, Isenberg DA. Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. Ther Adv Musculoskelet Dis. 2017 Mar;9(3):75-85. doi: 10.1177/1759720X17690474. Epub 2017 Mar 01. PMID: 28344669; PMCID: PMC5349337.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Musculoskelet Dis. 2017 Mar;9(3):75-85. doi: 10.1177/1759720X17690474. Epub 2017 Mar 01.

Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness.

Therapeutic advances in musculoskeletal disease

Sara Guerreiro Castro, David A Isenberg

Affiliations

  1. Autoimmune Diseases Unit, Internal Medicine 7.2 Dept, Hospital Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal.
  2. Centre for Rheumatology, University College London, Room 424, 4th Floor Rayne Building, 5 University Street, London WC1E 6JF, UK.

PMID: 28344669 PMCID: PMC5349337 DOI: 10.1177/1759720X17690474

Abstract

Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials.

Keywords: belimumab; biologic therapy; immunosuppressive agents; systemic lupus erythematosus

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

References

  1. N Engl J Med. 2013 Apr 18;368(16):1528-35 - PubMed
  2. Lupus. 2016 Jun;25(7):699-709 - PubMed
  3. Ann Rheum Dis. 2012 Nov;71(11):1833-8 - PubMed
  4. J Rheumatol. 2014 Feb;41(2):300-9 - PubMed
  5. PLoS One. 2015 Oct 21;10(10):e0140843 - PubMed
  6. J Rheumatol. 2015 Dec;42(12 ):2288-95 - PubMed
  7. Lancet. 2011 Feb 26;377(9767):721-31 - PubMed
  8. Arthritis Res Ther. 2008;10(5):R109 - PubMed
  9. Arthritis Rheum. 2008 Aug;58(8):2453-9 - PubMed
  10. Lupus. 2013 Jan;22(1):63-72 - PubMed
  11. J Rheumatol. 2012 Aug;39(8):1632-40 - PubMed
  12. Arthritis Rheum. 2009 Sep 15;61(9):1143-51 - PubMed
  13. Lupus. 2013 Feb;22(2):144-54 - PubMed
  14. Lupus Sci Med. 2016 Jan 11;3(1):e000118 - PubMed
  15. Lupus Sci Med. 2014 Jun 26;1(1):e000031 - PubMed
  16. Ann Rheum Dis. 2014 May;73(5):838-44 - PubMed
  17. Scand J Rheumatol. 2016;45(2):103-6 - PubMed
  18. J Exp Med. 2000 Oct 2;192(7):953-64 - PubMed
  19. Rheum Dis Clin North Am. 2014 Aug;40(3):507-17, viii - PubMed
  20. Arthritis Rheumatol. 2016 Sep;68(9):2184-92 - PubMed
  21. Biomed Res Int. 2014;2014:704207 - PubMed
  22. Arthritis Rheum. 2011 Dec;63(12):3918-30 - PubMed
  23. Arthritis Rheum. 2009 Sep 15;61(9):1168-78 - PubMed
  24. Arthritis Rheum. 2012 Jul;64(7):2328-37 - PubMed
  25. Clin Exp Rheumatol. 2013 Jul-Aug;31(4):656 - PubMed
  26. Arthritis Rheum. 2013 Oct;65(10):2672-9 - PubMed
  27. Arthritis Rheum. 2012 Oct;64(10):3364-73 - PubMed
  28. Farm Hosp. 2015 May 01;39(3):161-70 - PubMed
  29. Arthritis Rheum. 2003 May;48(5):1332-42 - PubMed
  30. Arthritis Rheum. 2003 Nov;48(11):3253-65 - PubMed
  31. Ann Rheum Dis. 2012 Aug;71(8):1343-9 - PubMed

Publication Types